Clinical Trial Update: NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 trial of NOV120101 in non-small cell lung cancer with acquired resistance to first-generation EGFR inhibitors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NOV120101

Snippet

Sponsor: National OncoVenture | Conditions: Increased Drug Resistance | Phase 2 | Status: COMPLETED